PET Imaging Agents for 5-HT2C Receptors
5-HT2C 受体 PET 显像剂
基本信息
- 批准号:9193103
- 负责人:
- 金额:$ 23.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-01-01 至 2018-12-31
- 项目状态:已结题
- 来源:
- 关键词:AffinityAgonistAnimal ModelAnxietyAreaAutopsyBasic ScienceBindingBiodistributionBiological AssayBlood - brain barrier anatomyBrainBrain DiseasesCarbonCentral Nervous System DiseasesCerebellumCharacteristicsChemical StructureChemicalsClinical ResearchDataDiseaseDopamine ReceptorDrug abuseEquilibriumEvaluationFeeding behaviorsFunctional disorderFutureG-Protein-Coupled ReceptorsGlutamatesImageIn VitroIndenesIndolesInvestigationKineticsLabelLeadLigandsMacaca mulattaMeasurementMeasuresMediatingMental DepressionMental disordersMethodsMolecularNational Institute of Mental HealthNeuraxisNeurosciencesNeurosecretory SystemsObesityOrganParkinson DiseasePathologicPharmacologyPhysiologyPositron-Emission TomographyPreclinical Drug EvaluationProcessPropertyPsychotropic DrugsPublishingRadioactiveRadioactivityRadiolabeledRegulationReportingReproducibilityRestRoleSchizophreniaSerotoninSerotonin Receptor 5-HT2CSprague-Dawley RatsStructureStructure-Activity RelationshipSurfaceSystemTestingTherapeuticTimeTissuesTracerbasedensitydesigndopaminergic neuronfunctional statusimaging agentimaging potentialimaging studyin vivoin vivo imaginginterestlipophilicitymethyl groupmicroPETnervous system disorderneurobehavioralnonhuman primatenovelobesity treatmentprogramspublic health relevanceradiochemicalradioligandradiotracerserotonin receptortooltreatment strategyuptake
项目摘要
DESCRIPTION (provided by applicant): The serotonin 5-HT2C receptor (5-HT2CR) is abundantly expressed throughout the central nervous system (CNS), and is involved in a variety of neuroendocrine and neurobehavioral processes. Evidence from animal models, postmortem tissues, and molecular neuroscience studies suggests that dysfunction of 5-HT2CR has been implicated in a number of significant neurological and psychiatric disorders, and 5-HT2CR has been identified as a target for the treatment of obesity, depression, anxiety, drug abuse, schizophrenia and Parkinson's disease. The unmet need is our inability to establish a direct relationship between 5-HT2CR physiology and brain diseases by accurately quantifying 5-HT2CR density and functional status in vivo using Positron Emission Tomography (PET), because there are no selective and specific PET radiotracer agonists or antagonists available for 5-HT2CR. The central objective of this proposal is to develop a carbon-11 5-HT2CR- specific radioligand antagonist with pharmacological and physiochemical properties for in vivo imaging studies by PET. The central hypothesis of this proposal is that a carbon-11 labeled bispyridyl-carbamoylindole derivative will enable mapping of both active and the resting states of 5-HT2C in a highly specific and sensitive manner. This hypothesis is based upon recent published reports and our preliminary findings on the excellent in vitro binding profiles of potent and selective 5-HT2CR antagonists, bispyridyl-carbamoylindoles. The central hypothesis will be tested by completing the following specific aims: 1. To synthesize and in vitro characterize bispyridyl-carbamoylindole derivatives. 2. To develop radiolabeling methods for the candidate 5-HT2CR ligand antagonist. 3. To determine whether radiolabeled candidate compounds will cross the blood brain barrier and the in vivo kinetic biodistribution in Sprague-Dawley rats is sufficient for quality PET imaging of 5-HT2CR. 4. To determine whether the lead candidate PET ligands show favorable distribution and kinetic properties for in vivo quantification of 5-HT2CR density in the brain of non-human primates.
描述(由申请人提供):5-羟色胺5-HT 2C受体(5-HT 2CR)在整个中枢神经系统(CNS)中大量表达,并参与多种神经内分泌和神经行为过程。来自动物模型、死后组织和分子神经科学研究的证据表明,5-HT 2CR的功能障碍与许多重要的神经和精神疾病有关,并且5-HT 2CR已被确定为治疗肥胖症、抑郁症、焦虑症、药物滥用、精神分裂症和帕金森病的靶点。未满足的需求是我们不能通过使用正电子发射断层扫描(PET)在体内准确定量5-HT 2CR密度和功能状态来建立5-HT 2CR生理学和脑疾病之间的直接关系,因为没有可用于5-HT 2CR的选择性和特异性PET放射性示踪剂激动剂或拮抗剂。该提案的中心目标是开发具有药理学和理化性质的碳-11 5-HT 2CR特异性放射性配体拮抗剂,用于PET体内成像研究。该提议的中心假设是碳-11标记的双吡啶基-氨基甲酰基吲哚衍生物将使得能够以高度特异性和灵敏度的方式映射5-HT 2C的活性和静息状态。这一假设是基于最近发表的报告和我们的初步研究结果的优秀的体外结合概况的有效和选择性的5-HT 2CR拮抗剂,双吡啶基-氨基甲酰吲哚。中心假设将通过完成以下具体目标进行检验:1.合成双吡啶基氨基甲酰吲哚衍生物并进行体外表征。2.建立5-HT 2CR配体拮抗剂的放射性标记方法。3.为了确定放射性标记的候选化合物是否会穿过血脑屏障,以及在Sprague-Dawley大鼠中的体内动力学生物分布是否足以用于5-HT 2CR的高质量PET成像。4.确定先导候选PET配体是否显示出有利的分布和动力学特性,用于非人灵长类动物脑中5-HT 2CR密度的体内定量。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mark Myron Goodman其他文献
Mark Myron Goodman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mark Myron Goodman', 18)}}的其他基金
Imaging Bacterial Infections in Vivo: First in Man Studies
体内细菌感染成像:人类研究中的首次
- 批准号:
10543621 - 财政年份:2021
- 资助金额:
$ 23.4万 - 项目类别:
Imaging Bacterial Infections in Vivo: First in Man Studies
体内细菌感染成像:人类研究中的首次
- 批准号:
10611527 - 财政年份:2021
- 资助金额:
$ 23.4万 - 项目类别:
Imaging Bacterial Infections in Vivo: First in Man Studies
体内细菌感染成像:人类研究中的首次
- 批准号:
10155704 - 财政年份:2021
- 资助金额:
$ 23.4万 - 项目类别:
Imaging bacterial infections with 2nd generation maltodextrins
使用第二代麦芽糊精对细菌感染进行成像
- 批准号:
10231244 - 财政年份:2020
- 资助金额:
$ 23.4万 - 项目类别:
Imaging bacterial infections with 2nd generation maltodextrins
使用第二代麦芽糊精对细菌感染进行成像
- 批准号:
10417147 - 财政年份:2020
- 资助金额:
$ 23.4万 - 项目类别:
Imaging bacterial infections with 2nd generation maltodextrins
使用第二代麦芽糊精对细菌感染进行成像
- 批准号:
10673086 - 财政年份:2020
- 资助金额:
$ 23.4万 - 项目类别:
18F Conjugated Maltodextrins for the Detection of Medical Device Infections
18F 共轭麦芽糖糊精用于检测医疗器械感染
- 批准号:
9056161 - 财政年份:2015
- 资助金额:
$ 23.4万 - 项目类别:
18F Conjugated Maltodextrins for the Detection of Medical Device Infections
18F 共轭麦芽糖糊精用于检测医疗器械感染
- 批准号:
9137678 - 财政年份:2015
- 资助金额:
$ 23.4万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 23.4万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 23.4万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 23.4万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 23.4万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 23.4万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 23.4万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 23.4万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 23.4万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 23.4万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 23.4万 - 项目类别: